Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (GI), hepatology, neurology and dermatology, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products, and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.

Employees

20,700

Sector

Pharmaceuticals

Calendar

02-24 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
26-01-16	6.980 $	-3.86%	1,533,139
26-01-15	7.260 $	-2.55%	1,810,786
26-01-14	7.450 $	-0.67%	1,297,985
26-01-13	7.500 $	+0.13%	1,913,718
26-01-12	7.490 $	+1.08%	1,297,327

Delayed Quote Nyse, January 16, 2026 at 04:00 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

6.980USD

Average target price

7.429USD

Spread / Average Target

+6.43%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nyse Other stock markets 16:00:02 2026-01-16 EST			5-day change	1st Jan Change
6.980 ^USD	-3.86%		-5.80%	+0.43%

01-14	Bausch Health Companies Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 03:45 PM
01-13	Bausch Health Brief: Co Provides Filing Ahead of Participating in 44th Annual J.P. Morgan Healthcare Conference on Jan. 14, 2026	MT

Capitalization	2.59B 2.23B 2.08B 1.93B 3.6B 235B 3.87B 23.87B 9.41B 112B 9.7B 9.5B 409B	P/E ratio 2025 *	5.71x	P/E ratio 2026 *	4.85x
Enterprise value	2.59B 2.23B 2.08B 1.93B 3.6B 235B 3.87B 23.87B 9.41B 112B 9.7B 9.5B 409B	EV / Sales 2025 *	0.25x	EV / Sales 2026 *	0.25x
Free-Float	88.99%	Yield 2025 *	-	Yield 2026 *	-

01-14	Bausch Health Companies Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 03:45 PM
01-13	Bausch Health Brief: Co Provides Filing Ahead of Participating in 44th Annual J.P. Morgan Healthcare Conference on Jan. 14, 2026	MT
01-13	Bausch Health Brief: Management Expects to Reaffirm FY25 Guidance at Higher End of Range for Itself Excluding Bausch + Lomb As Provided In October	MT
01-07	Truist Securities Adjusts Price Target on Bausch Health to $8 From $7, Maintains Hold Rating	MT
01-02	Bausch + Lomb Completes Refinancing of Outstanding Term B Loans	MT
12-29	Bausch Health Companies Inc. and 1261229 B.C. Ltd. Completes the Previously announced Offers to Exchange it?s Outstanding 4.875% Senior Secured Notes Due 2028 and 11.00% Senior Secured Notes Due 2028	CI
12-12	Bausch + Lomb Refinancing Outstanding Term B Loans	MT
12-12	Bausch + Lomb Brief: Announcing Refinancing of Outstanding Term B Loans	MT
12-09	Bausch Health Companies Inc. Announces Early Results of Senior Secured Notes Exchange Offers Announced	CI
12-02	Bausch Health Companies Inc. Presents at Evercore 8th Annual Healthcare Conference, Dec-02-2025 10:50 AM
12-01	Sector Update: Health Care Stocks Decline Late Afternoon	MT
12-01	Sector Update: Health Care Stocks Decline Monday Afternoon	MT
12-01	TSX Down 140 Points at Midday With Info Tech The Worst Performer	MT

01-07	Truist Securities Adjusts Price Target on Bausch Health to $8 From $7, Maintains Hold Rating	MT
25-10-29	Needham Keeps Hold on Bausch + Lomb After Q3, Says Would Like Clarity on Bausch Health Separation	MT
25-10-22	RBC Maintains Market Perform Rating, US$10 Price Target on Bausch Health Companies	MT
25-07-31	RBC Maintains US$10 Price Target, Sector Perform Rating on Bausch Health	MT
25-04-21	BofA Cuts Price Target on Bausch Health to $5 From $7	MT

Bausch Health Companies Inc. Stock

Equities

BHC

CA0717341071

Pharmaceuticals

Valuation: Bausch Health Companies Inc.

Chart: Bausch Health Companies Inc.

Latest news: Bausch Health Companies Inc.

Last Transcript: Bausch Health Companies Inc.

Analysts' recommendations: Bausch Health Companies Inc.

Press Releases: Bausch Health Companies Inc.

News in other languages: Bausch Health Companies Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Bausch Health Companies Inc.

ETFs: Bausch Health Companies Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

11-19	Bausch Health to Participate in the 8th Annual Evercore Healthcare Conference	AQ
25-10-30	Bausch: Q3 Earnings Snapshot	AQ
25-09-08	Bausch Health's Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin Tightening Treatments with Thermage Non-Surgical System	AQ
25-09-01	Bausch Health Launches YUN Probiotherapy ACN Skincare Line in Poland	AQ
25-08-27	Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025	AQ

25-02-20	En direct des marchés : Schneider rit, Carrefour pleure et Apple sort un iPhone "abordable"
25-02-20	Joyeux anniversaire, Donald
24-10-18	MÄRKTE USA/Rekordjagd geht weiter - Netflix mit starken Zahlen
24-10-18	MÄRKTE USA/Auszeit nach Rekordjagd - Netflix mit starken Zahlen
24-10-18	MÄRKTE USA/Wall Street bleibt dank Netflix in Rekordnähe

1 day	-3.86%
1 week	-5.80%
Current month	+0.43%
1 month	+2.35%
3 months	+15.37%
6 months	+7.72%
Current year	+0.43%

1 week	6.97	7.73
1 month	6.74	8
Current year	6.92	8
1 year	4.25	8.68
3 years	3.96	11.46
5 years	3.96	34.8
10 years	3.96	101.4

Manager	Title	Age	Since
Thomas Appio CEO	Chief Executive Officer	63	2022-05-09
Jean-Jacques Charhon DFI	Director of Finance/CFO	60	2024-08-18
Mirza Dautbegovic COO	Chief Operating Officer	-	-

Director	Title	Age	Since
Sandra Leung BRD	Director/Board Member	65	2025-07-21
Robert Power CHM	Chairman	69	2022-05-09
John Paulson CHM	Chairman	70	2022-06-22

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
BAUSCH HEALTH COMPANIES INC.	-3.86%	-5.80%	-6.18%	-9.82%	2.59B
ELI LILLY AND COMPANY	+0.53%	-2.37%	+43.09%	+190.27%	930B
JOHNSON & JOHNSON	-0.41%	+6.98%	+48.72%	+26.86%	527B
ABBVIE INC.	-0.31%	-2.60%	+24.94%	+40.25%	379B
ROCHE HOLDING AG	+0.93%	+2.38%	+31.46%	+18.47%	371B
ASTRAZENECA PLC	+0.19%	-1.15%	+28.47%	+21.14%	292B
NOVARTIS AG	+0.98%	+1.37%	+29.42%	+35.03%	276B
MERCK & CO., INC.	-1.93%	-1.54%	+11.14%	-1.47%	270B
NOVO NORDISK A/S	+6.49%	+1.95%	-32.44%	-18.44%	268B
AMGEN INC.	+0.12%	+1.32%	+21.43%	+22.64%	178B
Average	+0.27%	+0.05%	+20.00%	+32.49%	349.35B
Weighted average by Cap.	+0.59%	+0.50%	+29.02%	+65.17%

	2025 *	2026 *
Net sales	10.18B 8.77B 8.17B 7.6B 14.16B 923B 15.23B 93.96B 37.05B 441B 38.17B 37.38B 1,608B	10.52B 9.07B 8.44B 7.86B 14.64B 955B 15.75B 97.13B 38.3B 455B 39.46B 38.64B 1,663B
Net income	458M 395M 368M 342M 637M 41.56B 685M 4.23B 1.67B 19.82B 1.72B 1.68B 72.38B	541M 466M 434M 404M 753M 49.09B 810M 4.99B 1.97B 23.41B 2.03B 1.99B 85.5B
Net Debt	-	-